Federated Hermes Inc. Has $185,000 Position in Royalty Pharma plc (NASDAQ:RPRX)

Federated Hermes Inc. reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 22.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Federated Hermes Inc.’s holdings in Royalty Pharma were worth $185,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Inspire Investing LLC boosted its position in Royalty Pharma by 175.1% during the first quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock valued at $1,322,000 after purchasing an additional 27,701 shares during the last quarter. APG Asset Management US Inc. acquired a new position in Royalty Pharma during the fourth quarter valued at approximately $2,100,000. New Century Financial Group LLC acquired a new position in Royalty Pharma during the first quarter valued at approximately $1,091,000. Patient Capital Management LLC acquired a new position in Royalty Pharma during the fourth quarter valued at approximately $35,247,000. Finally, Rhenman & Partners Asset Management AB boosted its position in Royalty Pharma by 186.5% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 429,697 shares of the biopharmaceutical company’s stock valued at $12,070,000 after purchasing an additional 279,697 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $27.71 on Wednesday. The firm has a market cap of $16.55 billion, a P/E ratio of 20.68, a price-to-earnings-growth ratio of 4.17 and a beta of 0.46. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78. Royalty Pharma plc has a 1-year low of $25.20 and a 1-year high of $31.66. The business’s 50 day moving average is $28.02 and its 200-day moving average is $27.96.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The company had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter last year, the company earned $0.85 earnings per share. Equities research analysts predict that Royalty Pharma plc will post 4.04 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were paid a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.03%. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. The Goldman Sachs Group raised their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a research report on Monday, June 3rd. Morgan Stanley raised their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Royalty Pharma has an average rating of “Moderate Buy” and an average price target of $42.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.